DK0800399T3 - Kombineret terapeutisk behandling af hyperproliferative sygdomme - Google Patents

Kombineret terapeutisk behandling af hyperproliferative sygdomme

Info

Publication number
DK0800399T3
DK0800399T3 DK96901387T DK96901387T DK0800399T3 DK 0800399 T3 DK0800399 T3 DK 0800399T3 DK 96901387 T DK96901387 T DK 96901387T DK 96901387 T DK96901387 T DK 96901387T DK 0800399 T3 DK0800399 T3 DK 0800399T3
Authority
DK
Denmark
Prior art keywords
hyperproliferative diseases
therapeutic treatment
combined therapeutic
period
separate
Prior art date
Application number
DK96901387T
Other languages
Danish (da)
English (en)
Inventor
Bruno Tocque
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK0800399T3 publication Critical patent/DK0800399T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96901387T 1995-01-17 1996-01-12 Kombineret terapeutisk behandling af hyperproliferative sygdomme DK0800399T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
DK0800399T3 true DK0800399T3 (da) 2002-12-02

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96901387T DK0800399T3 (da) 1995-01-17 1996-01-12 Kombineret terapeutisk behandling af hyperproliferative sygdomme

Country Status (21)

Country Link
US (3) US6262032B1 (fi)
EP (1) EP0800399B1 (fi)
JP (3) JP4580469B2 (fi)
KR (1) KR100385266B1 (fi)
AT (1) ATE222109T1 (fi)
AU (1) AU716364B2 (fi)
BR (1) BR9606969A (fi)
CA (1) CA2209771C (fi)
CZ (1) CZ298710B6 (fi)
DE (1) DE69622989T2 (fi)
DK (1) DK0800399T3 (fi)
ES (1) ES2180729T3 (fi)
FI (1) FI119911B (fi)
FR (1) FR2729295A1 (fi)
HU (1) HU229484B1 (fi)
MX (1) MX9704490A (fi)
NO (1) NO325418B1 (fi)
PT (1) PT800399E (fi)
SI (1) SI0800399T1 (fi)
SK (1) SK283989B6 (fi)
WO (1) WO1996022101A1 (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
MXPA05014078A (es) * 2003-06-30 2006-05-25 Univ Lausanne Peptido derivado de rasgap para matar selectivamente celulas cancerosas.
EP1709973A1 (en) * 2003-12-24 2006-10-11 Locomogene, Inc. Method of suppressing cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614489B2 (en) * 1986-03-28 1991-09-05 Board Of Trustees Of The University Of Illinois, The Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0641193A4 (en) * 1992-05-20 1995-09-06 Daniel S Martin CHEMOTHERAPEUTIC DRUG COMBINATIONS.
AU691787B2 (en) * 1992-05-28 1998-05-28 Xenova Limited Treatment of cancers
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
WO1996022101A1 (fr) 1996-07-25
FR2729295B1 (fi) 1997-02-28
KR100385266B1 (ko) 2005-09-07
US20010021395A1 (en) 2001-09-13
MX9704490A (es) 1997-10-31
CA2209771C (fr) 2012-01-03
DE69622989T2 (de) 2002-12-05
FR2729295A1 (fr) 1996-07-19
ATE222109T1 (de) 2002-08-15
JP2012036201A (ja) 2012-02-23
NO973197D0 (no) 1997-07-09
US6262032B1 (en) 2001-07-17
US20040127437A1 (en) 2004-07-01
SK283989B6 (sk) 2004-07-07
FI119911B (fi) 2009-05-15
JPH10512559A (ja) 1998-12-02
JP4580469B2 (ja) 2010-11-10
DE69622989D1 (de) 2002-09-19
CZ226297A3 (en) 1997-10-15
CZ298710B6 (cs) 2008-01-02
ES2180729T3 (es) 2003-02-16
AU4542996A (en) 1996-08-07
JP2008133291A (ja) 2008-06-12
PT800399E (pt) 2002-12-31
JP5031921B2 (ja) 2012-09-26
US20050209177A9 (en) 2005-09-22
FI973023A0 (fi) 1997-07-16
HUP9802423A2 (hu) 1999-02-01
KR19980701449A (ko) 1998-05-15
HUP9802423A3 (en) 2000-11-28
CA2209771A1 (fr) 1996-07-25
US7884082B2 (en) 2011-02-08
NO325418B1 (no) 2008-04-21
BR9606969A (pt) 1997-11-04
HU229484B1 (en) 2014-01-28
SI0800399T1 (en) 2002-12-31
SK95797A3 (en) 1997-12-10
EP0800399B1 (fr) 2002-08-14
EP0800399A1 (fr) 1997-10-15
AU716364B2 (en) 2000-02-24
FI973023A (fi) 1997-07-16
NO973197L (no) 1997-07-09

Similar Documents

Publication Publication Date Title
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DK0800399T3 (da) Kombineret terapeutisk behandling af hyperproliferative sygdomme
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
PT998287E (pt) Utilizacao de levobupivacaina
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
DE60127552D1 (de) Intrakorporelle medikamente zur hoch-energetischen phototherapeutischen behandlung von krankheiten
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
ID24922A (id) Terapi kombinasi untuk pengobatan aids
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
TR199801887A2 (xx) Bir Na+/H+ - de�i�tiricisi inhibit�r�.
NO981020D0 (no) Transdermalt terapautisk system for silatranforbindelser
SE9803276D0 (sv) Use of certain drugs for treating nerve root injury
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
GEP19991781B (en) Means for Treatment of Prostate Diseases